Use of derivatives containing c-o-p bonds in patients with kidney failure

A method for the treatment and/or prevention of a kidney failure-related disease in a subject with kidney failure comprising administering to a subject in need an effective amount of a medicament which comprises at least one compound of formula I, or a pharmaceutical acceptable salt thereof:

• where:
• each R1 to R12 independently represents H, —X, —OX, —NHX, —NX2, —SX, —OSO3HX, —OSO3X2 or a compound of formula II:
• where each X independently represents H, C1-30alkyl, C2-30alkenyl, C2-30alkynyl or Cy1, where C1-30alkyl, C2-30alkenyl and C2-30alkynyl are independently optionally substituted by one or more R14 and where Cy1 is optionally substituted by one or more R15;
• Cy1 represents a carbocyclic or heterocyclic three- to 10-membered ring, which may be saturated, partially unsaturated or aromatic, where said heterocycle has between one and four heteroatoms selected from amongst O, S and N, where said ring can be bound to the rest of the molecule via any available C atom and where Cy1 is optionally fused to between one and four five- or six-membered rings, each saturated, partially unsaturated or aromatic, carbocyclic or heterocyclic, and where said fused heterocycle may contain one or two heteroatoms selected from amongst O, N and S;
• each R13 independently represents H, C1-30alkyl, —NH2, —NHC1-30alkyl or —N(C1-30alkyl)2, where each C1-30alkyl is independently optionally substituted with one or more halogen, —OH, —CN and —NO2 groups;
• and
• each R14 and R15 independently represents —OH, C1-30alkoxy, C1-30alkylthionyl, C1-30acyloxy, phosphate, halogen, trihaloC1-30alkyl, nitrile or azide,
• with the condition that at least one of R1 to R12 independently represents a compound of formula II,
• characterised in that said medicament is administered in a prolonged release form.